says Brad Loncar of Loncar Investments Viva Biotech is the fourth largest company in China’s drug discovery services industry, with a 2.6 per cent market share. Photo: Bloomberg Viva Biotech’s hugely …
( read original story …)
Home BUSINESS Investors pile into Viva Biotech’s Hong Kong IPO as they are confident of the R&D services provider’s business model
Categories
Beijing
22°
overcast clouds
humidity: 21%
wind: 1m/s SW
H 22 • L 20
Weather from OpenWeatherMap
Recent Posts
- China’s helium export ban rattles semiconductor supply chain already hit by West Asia crisis 17/07/2026
- Import prices post surprise gain as costs of goods from China hit highest since 2008 17/07/2026
- U.S. import prices rose in June 2026 as China goods costs surged 17/07/2026
- China dismisses Trump election interference accusations as ‘entirely fabricated,’ threatens countermeasures 17/07/2026
- White House reshares CIA director post as China-tech stakes reach the Fed 17/07/2026
- Beijing Rejects Trump’s Claim of Meddling, but Avoids a Fight 17/07/2026
- China warns of reciprocal countermeasures after US shortens foreign journalist visas 17/07/2026
- Awards for Excellence country/territory winners 2026: China’s best international bank – HSBC 17/07/2026
- China ‘strongly dissatisfied’ with nationalisation of British Steel 17/07/2026
- Trump’s allegations of Chinese interference in US elections stir tensions with Beijing 17/07/2026
- Will Manila and Hanoi’s maritime deal challenge Beijing in the South China Sea? 17/07/2026
- China responds to Trump’s bombshell election interference claim 17/07/2026
